المؤلفون: Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf

المساهمون: University of Zurich

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business

وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/

المؤلفون: Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni

المساهمون: University of Zurich, Dummer, Reinhard

المصدر: The Lancet Oncology. 19:1315-1327

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business

وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2

المؤلفون: Vanna Chiarion-Sileni, Ana Arance, Keith T. Flaherty, Ralf Gutzmer, Claus Garbe, Ivana Krajsová, Dirk Schadendorf, Naoya Yamazaki, Caroline Robert, Helen Gogas, Michael D Pickard, Caroline Dutriaux, Laure Moutouh-de Parseval, Jan Willem de Groot, Carmen Loquai, Paolo A. Ascierto, Victor Sandor, Mario Mandalà, Reinhard Dummer, Gabriella Liszkay

المصدر: The Lancet Oncology. 19:603-615

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Time Factors, Phases of clinical research, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, Progression-free survival, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Sulfonamides, Performance status, business.industry, MEK inhibitor, Binimetinib, Middle Aged, medicine.disease, Progression-Free Survival, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Mutation, Benzimidazoles, Female, Carbamates, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b9a8d731aee37b91ba57a2467a28bbTest
https://doi.org/10.1016/s1470-2045Test(18)30142-6

المؤلفون: Pascal Wolter, Dirk Schadendorf, Daniil Stroiakovski, Michael Lichinitser, Jeff Legos, Paul Nathan, Peng Sun, Kamil Drucis, Keith T. Flaherty, Boguslawa Karaszewska, Antoni Ribas, Florent Grange, Anne-Marie Martin, Shonda M Little, Reinhard Dummer, Ivana Krajsová, Laurent Mortier, Vanna Chiarion-Sileni, Wendy A. Crist, Paul Lorigan, Stephen D. Rubin, Andrzej Mackiewicz, Piotr Rutkowski, Jacob Schachter, Caroline Robert, Georgina V. Long, Axel Hauschild

المساهمون: University of Zurich, Robert, Caroline

مصطلحات موضوعية: Oncology, Male, Keratoacanthoma, Indoles, Skin Neoplasms, Medizin, Kaplan-Meier Estimate, 2700 General Medicine, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Oximes, Vemurafenib, Melanoma, Trametinib, Aged, 80 and over, education.field_of_study, Sulfonamides, Hazard ratio, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, Intention to Treat Analysis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Pyridones, Population, 610 Medicine & health, Pyrimidinones, Young Adult, Internal medicine, medicine, Humans, education, neoplasms, Protein Kinase Inhibitors, Aged, Cobimetinib, Mitogen-Activated Protein Kinase Kinases, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, chemistry, Mutation, business

وصف الملف: Robert C et al. - N Engl J Med 2014.pdf - application/pdf; Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb174f02e29f4375b8bd8c23ddb74764Test
https://doi.org/10.5167/uzh-107163Test

المؤلفون: Daniil Stroyakovskiy, Peter Mohr, Virginia Ferraresi, Michael Millward, Paul Nathan, Claus Garbe, Filippo de Braud, Caroline Robert, Jhangir G. Irani, Igor Bondarenko, Vanna Chiarion-Sileni, Jochen Utikal, Nadezhda Kovalenko, Douglas J Demarini, Bijoyesh Mookerjee, James Larkin, Ana Arance, Suzanne Swann, Mario Mandalà, Axel Hauschild, Jeffrey J. Legos, John B. A. G. Haanen, Jean-Jacques Grob, Keith T. Flaherty, Antoni Ribas, Johan Hansson, Dirk Schadendorf, Georgina V. Long, Thomas Jouary, Helen Gogas, Fan Jin, Volodymr Probachai, Céleste Lebbé, Evgeny Levchenko

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, medicine.medical_specialty, Pyridones, Medizin, Phases of clinical research, Pyrimidinones, Placebo, Disease-Free Survival, Young Adult, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Oximes, medicine, Clinical endpoint, Humans, Melanoma, Aged, Aged, 80 and over, Trametinib, Cobimetinib, business.industry, Hazard ratio, Imidazoles, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Treatment Outcome, chemistry, Drug Therapy, Combination, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7305a840ef7860ce6dbedc881e5fe7cfTest
http://hdl.handle.net/11391/1480871Test

المؤلفون: Daniil Stroyakovskiy, Jochen Utikal, Keith T. Flaherty, Daniele Ouellet, Virginia Ferraresi, Michelle Casey, Claus Garbe, Axel Hauschild, V. Chiarion Sileni, Caroline Robert, Helen Gogas, Antoni Ribas, Michael Millward, Nadezhda Kovalenko, Jean-Jacques Grob, Jhangir G. Irani, Paul Nathan, Dirk Schadendorf, John B. A. G. Haanen, V. Probachai, Mario Mandalà, F. de Braud, Johan Hansson, Georgina V. Long, Igor Bondarenko, Kiran Patel, Ngocdiep T. Le, Anne-Marie Martin, James Larkin, Ana Arance, T. Jouary, Peter Mohr, Douglas J. DeMarini, Céleste Lebbé, Evgeny Levchenko

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Fever, Pyridones, Medizin, Kaplan-Meier Estimate, Pyrimidinones, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Carcinoma, medicine, Clinical endpoint, Humans, Melanoma, Aged, Mitogen-Activated Protein Kinase Kinases, Cobimetinib, Trametinib, business.industry, Hazard ratio, Imidazoles, Binimetinib, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, chemistry, Mutation, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d13e0581ba3c486d28c2d159ca1daTest
http://hdl.handle.net/11391/1480877Test

المؤلفون: Kerstin Trunzer, Antoni Ribas, C. Lebbé, Dirk Schadendorf, Paul B. Chapman, Jeffrey A. Sosman, Axel Hauschild, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, Grant A. McArthur, Michele Maio, John M. Kirkwood, Thomas Jouary, Brigitte Dréno, Alexander M.M. Eggermont, John B. A. G. Haanen, James Larkin, Claus Garbe, Reinhard Dummer, Ivor Caro, Ming Yin, Paul Lorigan, Stephen J O'Day, Suzanne Cheng, David Hogg, Keith T. Flaherty, Caroline Robert

المساهمون: University of Zurich, McArthur, Grant A

المصدر: The Lancet. Oncology, vol 15, iss 3

مصطلحات موضوعية: Male, Indoles, Medizin, Gastroenterology, chemistry.chemical_compound, Vemurafenib, Melanoma, Cancer, Sulfonamides, education.field_of_study, Hazard ratio, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Dacarbazine, Oncology, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Population, 610 Medicine & health, Disease-Free Survival, Clinical Research, Internal medicine, Genetics, medicine, Humans, Oncology & Carcinogenesis, education, Protein Kinase Inhibitors, Aged, Cobimetinib, Performance status, business.industry, Prevention, medicine.disease, Surgery, Good Health and Well Being, chemistry, Mutation, business, Follow-Up Studies

وصف الملف: 573_McArthur_GA_et_al._-_Lancet_Oncol_2014.pdf - application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4Test
http://hdl.handle.net/11365/1081256Test

المؤلفون: Keith T, Flaherty, Caroline, Robert, Peter, Hersey, Paul, Nathan, Claus, Garbe, Mohammed, Milhem, Lev V, Demidov, Jessica C, Hassel, Piotr, Rutkowski, Peter, Mohr, Reinhard, Dummer, Uwe, Trefzer, James M G, Larkin, Jochen, Utikal, Brigitte, Dreno, Marta, Nyakas, Mark R, Middleton, Jürgen C, Becker, Michelle, Casey, Laurie J, Sherman, Frank S, Wu, Daniele, Ouellet, Anne-Marie, Martin, Kiran, Patel, Dirk, Schadendorf, Mary, Richardson

المصدر: The New England journal of medicine. 367(2)

مصطلحات موضوعية: Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Dacarbazine, MAP Kinase Kinase 2, Medizin, MAP Kinase Kinase 1, Antineoplastic Agents, Kaplan-Meier Estimate, Pyrimidinones, Disease-Free Survival, chemistry.chemical_compound, Young Adult, Internal medicine, medicine, Humans, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Trametinib, Cobimetinib, Aged, 80 and over, business.industry, MEK inhibitor, Hazard ratio, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Intention to Treat Analysis, chemistry, Mutation, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778f247f586f7abe700c37ec7f75715aTest
http://ora.ox.ac.uk/objects/uuid:17a4cd0c-72ea-46f7-ab36-457c375b3557Test